Gene therapy

Voyager Therapeutics Provides Update on the RESTORE-1 Parkinson’s Disease Trial

Friday, April 3, 2020 - 1:30pm

CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today provided an update on the RESTORE-1 clinical trial of VY-AADC (NBIb-1817) for Parkinsons disease.

Key Points: 
  • CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today provided an update on the RESTORE-1 clinical trial of VY-AADC (NBIb-1817) for Parkinsons disease.
  • Voyager and Neurocrine Biosciences continue preparations for the initiation of the RESTORE-2 registrational study in Parkinsons disease planned for the second half of 2020.
  • Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases.
  • Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Kaleido Biosciences Appoints Anne Prener, M.D., Ph.D., to its Board of Directors

Friday, April 3, 2020 - 1:30pm

Dr. Prener has led companies and teams across several therapeutic areas, including a focus on rare diseases.

Key Points: 
  • Dr. Prener has led companies and teams across several therapeutic areas, including a focus on rare diseases.
  • Prior to joining Freeline, she served as CEO of Gyroscope Therapeutics Ltd., a gene therapy company focused on eye diseases.
  • Dr. Prener serves on the Boards of Directors of several life science companies, Rubius Therapeutics, Cellinta and Renovacor.
  • I look forward to working with the Board and talented leadership team as Kaleido continues to progress its programs and overall business, said Dr. Prener.

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Friday, April 3, 2020 - 12:00pm

Vesting of each option award is subject to continued service with AVROBIO by the employee through the applicable vesting dates.

Key Points: 
  • Vesting of each option award is subject to continued service with AVROBIO by the employee through the applicable vesting dates.
  • Our mission is to free people from a lifetime of genetic disease with a single dose of gene therapy.
  • AVROBIO is powered by the plato gene therapy platform, our foundation designed to scale gene therapy worldwide.
  • AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Cell Therapy Processing Market to Reach $12.06 Bn, Globally, by 2026 at 27.8% CAGR: Allied Market Research

Thursday, April 2, 2020 - 2:29pm

Increase in the incidence of cardiovascular diseases and surge in the demand for chimeric antigen receptor (CAR) cell therapy propel the global cell therapy processing market.

Key Points: 
  • Increase in the incidence of cardiovascular diseases and surge in the demand for chimeric antigen receptor (CAR) cell therapy propel the global cell therapy processing market.
  • Based on offering type, the products segment contributed to more than four-fifths of the total share of the global cell therapy processing market in 2018 and is expected to maintain its leadership position throughout the forecast period.
  • Based on application, the skeletal muscle segment accounted for the largest market share of the global cell therapy processing market in 2018, accounting for more than one-fifth of the total market share in 2018.
  • Moreover, Asia-Pacific is expected to maintain the highest CAGR of 29.0% from 2019 to 2026, owing to presence of huge patient base, increase in research and development expenditure, and surge in usage of cell therapy processing products.

Cell Therapy Processing Market to Reach $12.06 Bn, Globally, by 2026 at 27.8% CAGR: Allied Market Research

Thursday, April 2, 2020 - 2:25pm

Increase in the incidence of cardiovascular diseases and surge in the demand for chimeric antigen receptor (CAR) cell therapy propel the global cell therapy processing market.

Key Points: 
  • Increase in the incidence of cardiovascular diseases and surge in the demand for chimeric antigen receptor (CAR) cell therapy propel the global cell therapy processing market.
  • Based on offering type, the products segment contributed to more than four-fifths of the total share of the global cell therapy processing market in 2018 and is expected to maintain its leadership position throughout the forecast period.
  • Based on application, the skeletal muscle segment accounted for the largest market share of the global cell therapy processing market in 2018, accounting for more than one-fifth of the total market share in 2018.
  • Moreover, Asia-Pacific is expected to maintain the highest CAGR of 29.0% from 2019 to 2026, owing to presence of huge patient base, increase in research and development expenditure, and surge in usage of cell therapy processing products.

Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic

Thursday, April 2, 2020 - 2:00pm

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders.
  • The companys platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients contending with rare genetic diseases.
  • Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition.
  • Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes.

StrideBio Appoints Maritza Mcintyre, Ph.D., As Chief Development Officer

Thursday, April 2, 2020 - 1:00pm

RESEARCH TRIANGLE PARK, N.C., April 2, 2020 /PRNewswire/ -- StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the appointment of Maritza McIntyre, Ph.D., as Chief Development Officer.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 2, 2020 /PRNewswire/ -- StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the appointment of Maritza McIntyre, Ph.D., as Chief Development Officer.
  • Dr. McIntyre is a virologist with over 20 years of experience in the development, evaluation and regulation of gene therapy, biological and small molecule products.
  • "We are delighted to have Dr. McIntyre join the StrideBio team as Chief Development Officer," said Sapan Shah, Ph.D., Chief Executive Officer.
  • I look forward to leading StrideBio's programs through this next phase of translational development and into the clinic."

Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

Thursday, April 2, 2020 - 12:30pm

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that management will participate in the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day on Friday, April 3, 2020.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that management will participate in the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day on Friday, April 3, 2020.
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders.
  • The companys platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients contending with rare genetic diseases.
  • Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition.

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

Wednesday, April 1, 2020 - 1:30pm

SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in two upcoming virtual investor conferences.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in two upcoming virtual investor conferences.
  • Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
  • Allogene Therapeutics, with headquarters inSouth San Francisco, is a clinical-stagebiotechnology company pioneering the development of allogeneic chimeric antigen receptor Tcell (AlloCAR T) therapies for cancer.
  • Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

2020 Innovations in Bioreactors, Gene Therapy, Vermifiltration & Membranes for Desalination Processes - ResearchAndMarkets.com

Wednesday, April 1, 2020 - 11:54am

The "Innovations in Bioreactors, Gene Therapy, Vermifiltration, and Membranes for Desalination Processes" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Innovations in Bioreactors, Gene Therapy, Vermifiltration, and Membranes for Desalination Processes" report has been added to ResearchAndMarkets.com's offering.
  • This edition of the Industrial Bioprocessing TOE features trends and innovations in fixed bed and disposable bioreactors used for processing viral vaccines and for the production of recombinant proteins used in gene therapy.
  • The TOE features innovations based on the novel gasification systems that can be vital in converting biomass in to renewable energy.
  • Additionally, the TOE provides intelligence on the use of innovative membrane technologies that can enhance water permeability and selectivity to generate more freshwater from desalination processes.